TiraboschuiLuca Humanitas Research HospitalItaly

At the Università degli Studi di Milano – Bicocca, I built my foundation in oncology, pharmacology, and immunology. During my master’s internship at Humanitas University under Prof. Rescigno, I contributed to developing a universal anticancer vaccine for melanoma and sarcoma. This pivotal experience deepened my expertise in cancer immunology and inspired my commitment to innovative therapies. As part of the Unicanvax Consortium, I helped generate a biobank of patient-derived tumor cells and identified ER-stress-derived immunogenic peptides. I also collaborated on clinical trials assessing the vaccine’s potential in canine hemangiosarcoma and melanoma, reinforcing my passion for translational research. In 2021, I began my PhD at Humanitas University, focusing on the intratumoral microbiota in soft tissue sarcomas—rare tumors with unmet clinical needs. I set up a new method for intratumoral Microbiome characterization through Next Generation Sequencing and I unveiled new insight regarding the chemoresistance mediated by intratumoral bacteria in the context of soft tissue sarcoma. My work has been recognized with two AIRC Pre-Doc Fellowships (2022 and 2023) and the Pezcoller Foundation Scholar-in-Training Award at AACR 2024. In January 2025 I completed my PhD at the Humanitas University with the thesis entitled: “Impact of intratumoral microbiota in soft tissue sarcoma treatment efficacy”.